Palatin Technologies receives grants under PPACA program

The grants are related to four of Palatin’s projects – melanocortin agonists for sexual dysfunction; melanocortin agonists for obesity and related metabolic syndrome; natriuretic peptide mimetic PL-3994 for acute asthma; and subcutaneously-delivered natriuretic peptide mimetic PL-3994 for cardiovascular disease.

Palatin said that it will receive $847,000 immediately and $131,000, 30 days after its fiscal year ending 30 June 2011.

Palatin Technologies is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.